From: Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study
With Fractures (n.18) | Without Fractures (n.82) | p | |
---|---|---|---|
Age (years) | 61 ± 13 | 61 ± 15 | 0.91 |
Male Sex (%) | 61 | 63 | 0.86 |
Duration of RDT (months) | 35 (14–75) | 44 (18–101) | 0.47 |
BMI (Kg/m2) | 26.8 ± 4.8 | 25.1 ± 4.4 | 0.18 |
Height (cm) | 159 ± 10 | 161 ± 10 | 0.48 |
Smokers (%) | 50 | 48 | 0.85 |
Diabetics (%) | 17 | 16 | 0.93 |
Treated with Beta blockers (%) | 6 | 21 | 0.13 |
Treated with Calcitriol (%) | 39 | 49 | 0.45 |
Treated with Ca-carbonate or Ca- acetate (%) | 83 | 87 | 0.72 |
Treated with ESAs (%) | 39 | 51 | 0.34 |
Hemodialysis/CAPD (n.) | 15/3 | 51/31 | 0.09 |
History of previous fractures (%) | 24 | 4 | 0.009 |
History of renal transplantation (%) | 6 | 10 | 0.56 |
Haemoglobin (g/dL) | 9.8 ± 2.6 | 10.5 ± 1.8 | 0.27 |
Serum Albumin (g/dl) | 4.0 ± 0.7 | 3.8 ± 0.6 | 0.27 |
Serum Calcium (mmol/L) | 4.5 ± 0.6 | 4.5 ± 0.6 | 0.73 |
Serum Phosphate (mg/dl) | 6.0 ± 1.4 | 6.0 ± 1.6 | 0.92 |
Intact PTH (pg/mL) | 319 (95–741) | 135 (53–346) | 0.04 |
intact PTH < 100 pg/ml (%) | 28 | 46 | 0.15 |
intact PTH > 800 pg/ml (%) | 22 | 6 | 0.03 |
Bone Alkaline phosphatase (μg/L) | 15.0 (6.4-21.2) | 12.7 (7.9-22.9) | 0.89 |
Total Alkaline phospatase (UI/L) | 67 (58–98) | 69 (51–86) | 0.88 |
IL-6 (pg/mL) | 6.1 (3.2-8.0) | 7.2 (3.3-11.0) | 0.50 |
CRP (mg/L) | 11.1 (3.5-28.2) | 8.9 (3.4-19.1) | 0.59 |
TNF-α (pg/mL) | 12.0 (6.4-13.4) | 7.8 (4.6-11.0) | 0.02 |